Piper Jaffray analyst Matt O’Brien raised his price target on Baxter to $83 after its Q2 earnings beat and raised FY18 EPS guidance. The analyst further notes that in addition to continued margin improvement, investors may be “overlooking revenue growth opportunities”. O’Brien keeps his Overweight rating on Baxter despite the 4% stock price decline from the headwinds in Medication Delivery and Nutrition, and believes the guidance provided by the management is on the conservative site, with “large share appreciation from potential capital deployment this year”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.